Septal Occluder Cleared for Use in Very Young Patients
February 20, 2008
W. L. Gore & Associates (Gore) announced that the FDA granted approval for the use of GORE HELEX Septal Occluder with a modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD), providing a percutaneous ASD closure solution for very young patients.
The GORE HELEX Septal Occluder is a permanently implanted prosthesis that uses ePTFE, a biocompatible material that allows tissue ingrowth, to seal the defect.
More like this
- FDA Clears Septal Occluder Use with Catheter Delivery System
- Gore Recognized as One of World’s Most Innovative Companies
- Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for PFO Closure
- International Study Examines Effectiveness of Gore Helex for PFO Closure in Patients With Cryptogenic Stroke
- Gore Hopeful for Positive PFO Occluder Trial Data